FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy
Lucie C. Kompier(Erasmus MC), Ellen C. Zwarthoff(Erasmus MC), Irene Lurkin(Erasmus University Rotterdam), Theodorus van der Kwast(Erasmus MC), Madelon N.M. van der Aa(Erasmus MC), Bas W.G. van Rhijn(The Netherlands Cancer Institute)
Cited by 314
Related Papers
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study
|The Lancet Oncology|2010|944
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|793
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
|Cancer Cell|2016|654
Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression
|Nature Cell Biology|2021|537
Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo.
|Proceedings of the National Academy of Sciences|1989|493